Biocytogen Pharmaceuticals Co. Ltd. has raised HK$471.1 million (US$60 million) in net proceeds through an initial public offering on the Hong Kong Stock Exchange Sept. 1. It plans to use about three-quarters of the proceeds to advance clinical trials of two of its core anticancer candidates, YH-003 and YH-001. Company shares (HKEX:2315), initially offered at HK$25.22 each, closed at HK$26 on their first trading day.
Sinocelltech Group Ltd. has received marketing approval for its recombinant chimeric anti-CD20 monoclonal antibody, ripertamab (SCT-400), from China’s NMPA to treat patients with CD20-positive diffuse large B-cell lymphoma. The country’s first homegrown anti-CD20 therapy, ripertamab has been shown to have similar efficacy to global blockbuster rituximab but with a superior safety profile.
Pleco Therapeutics BV has raised €17.3 million (US$17.1 million) in equity, loan and grant financing to move its lead program into a phase I trial next year. The company, based in Nijmegen, the Netherlands, is bringing a fresh perspective to bear on a longstanding therapeutic concept – that cancer can be tackled by metal chelation. Quite a number of agents have entered the clinic over the years, but none as yet has delivered any useful outcome.
Doxorubicin is widely used as an anticancer agent, but it is associated with cardiotoxicity. Follistatin like 3 (FSTL3) is known to be involved in the regulation of cardiac hypertrophy and heart failure.
To target mutant RAS in the GTP-bound RAS(ON) state for cancer treatment, Revolution Medicines Inc. has developed a platform in which binding and inhibition occur through small molecule-driven formation of a high-affinity ternary complex (tri-complex) between the target protein, a small molecule and a chaperone such as cyclophilin A.
Jacobio Pharmaceuticals Co. Ltd. has synthesized new protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Nanchang Helioeast Technology Co. Ltd. has identified new oxa-azaspiro compounds acting as lysine-specific histone demethylase 1A (KDM1A; LSD1) inhibitors reported to be useful for the treatment of acute myeloid leukemia.
RSS
